SRSF3 and familial pancreatic carcinoma: Wang et al. establishes a link between SRSF3, m6A modification, lncRNA splicing, and DNA HR in pancreatic cancer and demonstrates that abnormal alternative splicing and m6A modification are closely related to chemotherapy resistance in pancreatic cancer (Wang et al., 2022).